{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:24:32Z","timestamp":1788384272654,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jgo.2021.02.026","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:46:40Z","timestamp":1616086000000},"page":"1110-1113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma"],"prefix":"10.1016","volume":"12","author":[{"given":"Julie","family":"Valentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ferte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorilla","family":"Prey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Dousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pham-Ledard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jgo.2021.02.026_bb0005","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","article-title":"Cutaneous squamous cell carcinoma","volume":"78","author":"Que","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"S8","key":"10.1016\/j.jgo.2021.02.026_bb0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jdv.16024","article-title":"Medical treatment of advanced cutaneous squamous-cell carcinoma","volume":"33","author":"Gellrich","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jgo.2021.02.026_bb0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with Cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jgo.2021.02.026_bb0020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2021.02.026_bb0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2017.05.044","article-title":"Immune checkpoint inhibitors and elderly people: a review","volume":"82","author":"Daste","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2021.02.026_bb0030","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jgo.2020.03.003","article-title":"Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma","volume":"11(8)","author":"Barailler","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2021.02.026_bb0035","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"24","key":"10.1016\/j.jgo.2021.02.026_bb0040","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology Consensus on geriatric assessment in older patients with Cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2021.02.026_bb0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jgo.2019.05.021","article-title":"Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors","volume":"11","author":"Welaya","year":"2020","journal-title":"J Geriatr Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406821000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406821000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:52:59Z","timestamp":1761817979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406821000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1879406821000527"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2021.02.026","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2021.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}